A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Clinical trial NCT06793709 · RECRUITING
Trial details
- NCT number
- NCT06793709
- Sponsor
- Eisai Co., Ltd.
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-07-10
- Primary completion
- 2032-11-20
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.